NurExone Biologic Inc. (TSXV: NRX) shareholders approved a resolution authorizing a share consolidation at their annual general meeting on September 15, 2026. The measure passed with 97.61% support, granting the board flexibility to evaluate market conditions for a potential US exchange listing.

The approval allows the board to consolidate up to 30 pre-consolidation shares into one post-consolidation share at any time within the next 36 months. This authority is subject to TSXV acceptance and other regulatory approvals.

Voting Results

Shareholders represented 32,963,581 shares, or 34.90% of issued and outstanding shares as of the record date. All five director nominees were re-elected, with votes ranging from 95.37% to 99.96% in favor.

Other Resolutions

Disinterested shareholders re-approved the amended omnibus equity incentive plan with 99.17% support. Ziv Haft, CPA, was reappointed as auditor with 99.95% approval.

Capital Markets Strategy

NurExone entered a 12-month agreement with Acorn Management Partners to enhance visibility among US financial professionals. The cash-only arrangement carries a maximum aggregate base fee of US$180,000, payable from working capital. Acorn will not receive company securities.

What the Numbers Show

The high approval rate for the consolidation (97.61%) contrasts with the lower participation rate (34.90%). This indicates strong support from active holders but suggests limited engagement from the broader shareholder base, which may impact future capital-raising efforts.

NurExone Biologic Inc. (TSXV: NRX) reported a narrowed net loss for the second quarter ended June 30, 2026, driven by reduced administrative costs despite higher research spending. The biotechnology firm also secured US$1.2 million in gross proceeds through two private placements to support its working capital and pipeline advancement.

The company posted a net loss of US$1.68 million for the quarter, an improvement from the US$1.85 million loss recorded in the same period of 2025. This reduction was primarily attributable to a decline in general and administrative expenses, which fell to US$0.93 million from US$1.13 million year-ago, aided by lower professional services and legal costs.

Financial Performance

Research and development expenses rose to US$0.75 million from US$0.70 million in Q2 2025, reflecting increased material purchases and development activity for its lead product, ExoPTEN. Net financial expenses remained minimal at US$0.01 million, down from US$0.02 million previously, due to lower foreign currency translation adjustments.

What the Numbers Show

General and administrative expenses constituted approximately 55% of the total operating expenses in Q2 2026, while research and development accounted for the remaining 45%. The divergence between rising R&D spend and falling G&A indicates a strategic shift toward prioritizing clinical pipeline advancement over corporate overhead during this period.

Strategic Developments

NurExone advanced several key commercial and regulatory milestones:

• U.S. Manufacturing: Entered a binding memorandum of understanding with Made Scientific Inc. on August 12, 2026, for GMP manufacturing collaboration. Initial batches are targeted for H1 2027.
• Mexico Distribution: Subsidiary Exo-Top Inc. signed an MOU with ExoLyra LLC on June 24, 2026, securing exclusive rights to market exosome products in Mexico for three years, supported by a US$180,000 exclusivity fee.
• IP Expansion: Received patent grants in Korea and Australia covering ExoPTEN and extracellular vesicle bioproduction.
• Financing: Closed private placements in June and August 2026 raising aggregate gross proceeds of approximately US$1.2 million (C$1.69 million) for general working capital.